MTOR and biliary tract cancer: Two recent early‐phase clinical trials have demonstrated that a subgroup of patients with biliary tract cancer gain benefit from treatment with the mTOR inhibitor everolimus (Buzzoni et al., 2014; Yeung et al., 2014).